Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed new compounds targeting apolipoprotein A (ApoA; LPA) and acting as lipoprotein(a)-lowering agents that are potentially useful for the treatment of cardiovascular disorders.
Emory University has divulged new prostaglandin EP2 receptor (PTGER2) antagonists potentially useful for the treatment of cancer, neuropathic pain, hypertension, inflammatory bowel disease, Alzheimer’s disease, atherosclerosis, asthma and glomerulonephritis, among others.
Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has discovered new prodrugs of glucagon-like peptide 1 (GLP-1) polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, overweight, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, neurodegeneration, diabetic nephropathy and cardiovascular disorders, among others.
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson's disease, among others.
Acadia Pharmaceuticals Inc. has reported new G protein-coupled receptor GPR88 agonists that are potentially useful for the treatment of tardive dyskinesia.
Liver receptor homolog-1 (LRH-1) is a nuclear receptor that promotes the transcription of genes encoding key steroidogenic enzymes, thereby facilitating de novo androgen biosynthesis within the prostate tumor microenvironment. Researchers from Qilu Pharmaceutical Co. Ltd. reported the discovery and preclinical characterization of a series of novel LRH-1 antagonists.
Kinase inhibitors have shown success in disease areas such as oncology, but their application in neurodegenerative diseases is still limited. This is mainly due to several challenges, such as the complexity of kinase networks, limited blood-brain barrier permeability and the lack of biomarkers.
Researchers from Mabqi SAS presented the preclinical profile of MQI-181, an antibody-drug conjugate (ADC) composed of a human anti-CD30 antibody (18D03) linked to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable MC-VC-PAB linker, with a drug-antibody ratio of 4.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with increased oxidative stress. In this context, pharmacological activation of the Keap1-Nrf2 pathway, a key regulator of antioxidant and cytoprotective gene expression, has emerged as a promising therapeutic strategy to re-establish redox homeostasis and reduce inflammation in AD. Researchers from the Korea Institute of Science and Technology reported the design and preclinical characterization of a novel Nrf2 activator in models of AD.
RSS
